719. Systematic review of evidence for 2-dose HPV vaccination schedules
Session: Poster Abstract Session: Vaccines: Adolescent HPV and Meningococcal
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • HPV Vaccination Schedules Poster - FINAL.pdf (1.7 MB)
  • Background: In the United States, three HPV vaccines are licensed for use in a 3-dose schedule; the first was approved in 2006. To prevent HPV infections, anogenital warts, condyloma, and HPV-associated precancers and cancers, the Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination at age 11–12 years, and for females through age 26 and males through age 21 years. Interest in two-dose schedules has been stimulated by programmatic considerations including reduced costs and increased convenience for patients, parents, and health care providers.

    Methods: We conducted a systematic review of evidence evaluating HPV vaccine schedules in which two doses were administered at an interval of at least 6 months (±4 weeks) to girls or boys aged 9–14 years. We used keyword search terms including “HPV vaccine,” “papillomavirus vaccine,” “two dose” and “two doses” to identify studies in Pubmed and clinicaltrials.gov. Relevant studies included primary data on health outcomes following two-dose schedules of any HPV vaccine. Benefits and harms were tabulated and quality of evidence was evaluated using Grading of Recommendations, Assessment, Development and Evaluation (GRADE).

    Results: We identified and reviewed 105 studies of interest, selecting 15 relevant studies for inclusion in evidence tables. Studies of each of the three licensed HPV vaccines have demonstrated non-inferior immunogenicity with two doses of HPV vaccine administered 6 months apart, compared with 3-dose schedules administered at 0, 1–2, and 6 months to women in the age group for whom efficacy was demonstrated in clinical trials. Using GRADE criteria, there is moderate evidence supporting two-dose schedules for HPV vaccination.

    Conclusion: Two-dose schedules warrant careful attention from national policymakers. The Advisory Committee on Immunization Practices is reviewing these findings for policy considerations during 2016.

    Elissa Meites, MD, MPH and Lauri Markowitz, MD, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    E. Meites, None

    L. Markowitz, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.